Related Experiment Video

Updated: Sep 11, 2025

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.0K

Nanocarriers for Combination Therapy in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review

Iris Pontón1, David Sánchez-García1

  • 1Grup d'Enginyeria de Materials (GEMAT), Institut Químic de Sarrià (IQS), Universitat Ramon Llull (URL), Via Augusta 390, 08017 Barcelona, Spain.

Nanomaterials (Basel, Switzerland)
|August 13, 2025
PubMed

Insights

Nanoparticle drug delivery systems offer a promising strategy for pancreatic cancer combination therapies. These systems can co-deliver multiple drugs to effectively target the tumor microenvironment and overcome drug resistance.

Area of Science:

  • Oncology
  • Nanomedicine
  • Drug Delivery Systems

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with poor therapeutic outcomes.
  • Conventional monotherapies are often ineffective due to multidrug resistance (MDR) and a complex tumor microenvironment (TME).
  • Combination therapies are crucial for improving treatment efficacy in PDAC.

Purpose of the Study:

  • To review nanoparticle-based drug delivery systems (DDSs) for PDAC combination therapy.
  • To focus on systems co-delivering small-molecule drugs.
  • To analyze advancements in nanoparticle DDSs for PDAC from 2005-2025.

Main Methods:

  • Comprehensive literature review of studies on nanoparticle-based DDSs for PDAC.
  • Analysis of systems designed for combination therapy using small-molecule drugs.
  • Examination of controlled release mechanisms and TME targeting strategies.

Main Results:

  • Nanoparticle DDSs enable co-delivery of multiple agents for synergistic effects in PDAC.
  • These systems demonstrate potential in overcoming MDR and enhancing anti-tumor efficacy.
  • Various nanoparticle platforms show promise for targeted delivery and controlled release within the TME.

Conclusions:

  • Nanoparticle-based combination therapies represent a significant advancement in PDAC treatment.
  • DDSs offer a versatile platform for optimizing drug delivery and overcoming therapeutic challenges.
  • Further research into nanoparticle DDSs is warranted to translate these findings into clinical applications.
Keywords:
chemotherapycombination therapymulti-drug resistancenanomedicinenanoparticlespancreatic cancerpancreatic ductal adenocarcinomastromal therapy

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

904
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.2K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K